Global Cell and Gene Therapy Manufacturing Market Outlook (2023 to 2033)
Newly-released Cell and Gene Therapy Manufacturing Market analysis report by Future Market Insights shows that global sales of the Cell and Gene Therapy Manufacturing Market in 2022 were held at US$ 15.6 Billion. With a CAGR of 29% from2023 to 2033, the market is expected to reach a valuation of US$ 240 Billion.Market revenue through Cell Therapy Manufacturing is expected to be the highest revenue-generating segment, accounting for an expected CAGR of 31.8% from 2023 to 2033.
Attribute
Details
Global Cell and Gene Therapy Market (2023)
US$ 19.3 Billion
Global Cell and Gene Therapy Market (2033)
US$ 240 Billion
Global Cell and Gene Therapy Market CAGR (2023 to 2033)
29%
USA Cell and Gene Therapy Market CAGR (2023 to 2033)
28.5%
Key Companies Profiled
Thermo Fisher Scientific
Merck KGaA
Lonza
Catalent Inc.
Takara Bio Inc.
F. Hoffmann-La Roche Ltd
Wuxi Advanced Therapies
Samsung Biologics
Boehringer Ingelheim
Novartis AG
Hitachi Chemical Co., Ltd.
Cellular Therapeutics
Miltenyi Biotec
Bluebird Bio Inc.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Revenue of Cell and Gene Therapy Manufacturing Market from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033
As per the Cell and Gene Therapy Manufacturing Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 22% CAGR.
The rising frequency of cancer and other target diseases, as well as increasing research and development spending in pharmaceutical companies, are driving market expansion. GLOBOCAN 2020 has been revised by the International Agency for Research on Cancer (IARC), which reveals that the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020.
According to a new study, more than 50 million people will be diagnosed with cancer within the next five years. Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. Breast cancer is also one of every four cancers diagnosed in women worldwide, according to the same source.
Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer worldwide for the first time, owing to its high incidence in low- and middle-income nations. Because cancer is one of the most complex diseases, cell and gene therapy is one of the fields with a significant opportunity for cancer treatment.
Immunotherapy, gene transfer, and oncolytic virotherapy are three separate gene therapy treatment techniques that can be used to treat cancer. As the number of instances increases, so will the reliance on gene therapy, thus driving the market growth.
What are the factors driving the growth of the Cell and Gene Therapy Manufacturing Market?
There are around 1,200 cell and gene therapies in clinical trials globally. In the USA alone, there are over 700 investigational cell and gene therapies in clinical trials. Manufacturing facilities, on the other hand, have not kept up. Hundreds of more facilities are expected to be required to manufacture the therapies currently in clinical development. Viral capacity is one of the areas that has to be accelerated.
A large proportion of viral vectors are made utilizing adherent manufacturing, which is costly to run-a vial of 20 million cells can cost anywhere between US$ 20,000 and US$ 30,000 to generate. The cost of producing gene therapy can range from US$ 500,000 to US$ 1 million, excluding research and development, clinical trial costs, and the costs of establishing the commercial infrastructure required to offer access to patients.
Find your sweet spots for generating winning opportunities in this market.
Which Region is projected to Offer Significant Opportunity for the Cell and Gene Therapy Manufacturing Market?
The market in Asia Pacific is expected to offer a significant opportunity to the market owing to the continuous developments taking place in the regional marketplace. Best practices are being discovered in cell and gene therapy manufacturing as well as in scaling out strategies, process development, cost optimization, advancements in CAR-T manufacturing, and preparation for commercialization.
Companies such as BeiGene, Gracell Biotechnologies, Fosun Kite Biotechnology, Tessa Therapeutics, CARSgen, Senlang Bio, Kangstem Biotech, Medigen Biotechnology Corp, and Shangai UniCAR Therapy have been actively engaged in the advancement of concurrent techniques.
Country-wise Analysis
USA Cell and Gene Therapy Manufacturing Market Analysis
The USA accounted for a significant proportion of the cell and gene therapy manufacturing market revenues in 2022. The key driving factors for the market expansion in the country are a large number of active clinical trials, as well as the growing engagement of firms in gene and cell therapy research and development. With more than 400 businesses actively engaged in the development of cell and gene therapy products for various diseases, North America was ranked top for having the most gene therapy clinical trials.
United Kingdom Cell and Gene Therapy Manufacturing Market Analysis
The market in the United Kingdom is expected to reach a valuation of US$ 6.5 Billion by 2033. Growing with a CAGR of 23.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 5.7 Billion.
Japan Cardiovascular Ultrasound Market Analysis
In Japan, the market is expected to grow at a CAGR of 32.5% from 2023 to 2033, reaching US$ 12.6 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 11.9 Billion during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
What are the insights about the Therapy Type Segment of Cell and Gene Therapy Manufacturing?
Cell therapy manufacturing led the cell and gene therapy manufacturing market, accounting for a significant proportion of revenue. The high number of active clinical trials and the increasing number of goods entering the market are both contributing to the rise.
To understand the potential of cell therapies for the treatment of various cancer indications, more than 250 clinical trials concentrating on CAR T cell treatments and other cell therapies are explored. Furthermore, biopharma companies are seeing allogeneic CAR T cell therapy as a more attractive business strategy than traditional manufacturing and business models.
Why Pre-commercial Cell and Gene Therapy Manufacturing are Expected to be a Potential Market?
The robust and continually developing pipeline of cell and gene therapies around the world has fuelled the rise of the pre-commercial/ research and development scale manufacturing industry. More than 1,000 clinical trials for various cell treatments were currently conducted as of March 2020. According to the Journal of Gene Medicine, the number of gene therapy clinical studies increased to 3,025 in 2019. This high figure reflects the rising need for manufacturing services in the development of preclinical product candidates.
What are the insights in the Mode segment in Cell and Gene Therapy Manufacturing Market?
The key contribution to this area is the presence of a significant number of huge capital businesses, as well as academic institutes with tailored patient treatment programs. Greater process troubleshooting agility, ownership of supply channels, and the efficient development of a corporate knowledge base to aid future in-house scale-up are the prominent factors driving the segment growth.
The growing popularity of sophisticated medicines has heightened market competitiveness among participants. Contracts and agreements are being signed between cell therapy manufacturing businesses and CDMOs in order to accelerate product development and acquire a competitive advantage.
The contract-manufacturing segment's revenue has also been boosted by ongoing clinical research projects. Furthermore, more than 65% of the cell and gene therapy manufacturing process is outsourced, which is expected to further reduce costs and add to the market growth.
What are the insights about the Workflow segment?
The development of well-characterized and robust technologies for cell therapy production has become increasingly vital owing to an increasing number of medicines progressing from clinical trials to regulatory approval. Process development solutions improve the quality and safety profiles of candidate programs while increasing efficiency.
This segment, on the other hand, is predicted to increase at the fastest rate throughout the forecast period due to the significant penetration of manufacturing services in the vector production area. The viral vectors have been used to treat a variety of disorders, including cardiovascular, metabolic, hematologic, muscular, infectious, and ophthalmologic conditions, as well as numerous types of cancer.
Competitive Analysis
The growing interest of public and private investors in the development of advanced therapies is expected to boost market revenue during the forecast period. In addition, key firms are enhancing their market presence through strategic activities such as mergers and acquisitions, licensing, and partnerships.
Several noteworthy mergers and acquisitions have occurred in the market in recent years.
Some of the recent developments of key Cell and Gene Therapy Manufacturing providers are as follows:
In January 2022, Thermo Fisher Scientific bought Novasep’s viral vector production company. This agreement allowed the corporation to increase its global vector manufacturing capacity.
In February 2020, to strengthen its market footprint in cell and gene therapy platforms, Catalent Inc. announced the acquisition of MaSTherCell Global, Inc. for US$ 315 Million.
In December 2020, Be the Match and Lonza BioTherapies and BioTherapies formed a joint venture to develop the vein-to-vein cell and gene therapy supply chain network, primarily in North America and Europe.
Similarly, recent developments related to companies offering Cell and Gene Therapy Manufacturing have been tracked by the team at Future Market Insights, which are available in the full report.
Market Segments Covered in Cell and Gene Therapy Manufacturing Market Analysis
By Therapy Type:
Cell Therapy Manufacturing
Stem Cell Therapy
Non-Stem Cell Therapy
Gene Therapy Manufacturing
By Scale:
Pre-commercial/ R&D Manufacturing
Commercial Scale Manufacturing
By Mode:
Contract Manufacturing
In-house Manufacturing
By Workflow:
Cell Processing
Cell Banking
Process Development
Fill & Finish Operations
Analytical And Quality Testing
Raw Material Testing
Vector Production
Other Workflows
By Region:
North America
USA
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Middle East & Africa
South Africa
Saudi Arabia
UAE
Rest of the Middle East and Africa
Frequently Asked Questions
How Big is the Cell and Gene Therapy Manufacturing Market?
The cell and gene therapy manufacturing market is expected to reach US$ 19.3 billion in 2023.
What is the Anticipated CAGR of the Market?
The market is anticipated to expand at a CAGR of 29%.
Which Factor is Driving the Market Growth?
Constant developments and advancements in the cell and gene therapy manufacturing techniques are driving the market growth.
What is the Forecast CAGR of the United Kingdom Market?
The United Kingdom market for cell and gene therapy manufacturing is forecast to expand at a CAGR of 23.9%.
Who are the Market Leaders in the Cell and Gene Therapy Manufacturing Market?
The market leaders in the cell and gene therapy manufacturing market are Lonza, Catalent Inc., and Takara Bio Inc.
Table of Content
1. Executive Summary | Cell and Gene Therapy Manufacturing Marke
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage
2.2. Market Definition
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Cell And Gene Therapy Manufacturing
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ billion)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background
4.1. Cell And Gene Therapy Manufacturing Market, by Key Countries
4.2. Opportunity Assessment (US$ billion)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Growth in Automation, By Country
4.5.3. Cell And Gene Therapy Manufacturing Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Demand Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Analysis, 2018 to 2022
6.2. Current and Future Market Projections, 2023 to 2033
6.3. Y-o-Y Growth Trend Analysis
7. Global Value Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ billion) Analysis, 2018 to 2022
7.2. Current and Future Market Value (US$ billion) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ billion) Analysis By Therapy Type, 2018 to 2022
8.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Therapy Type, 2023 to 2033
8.3.1. Cell Therapy Manufacturing
8.3.1.1. Stem Cell Therapy
8.3.1.2. Non-Stem Cell Therapy
8.3.2. Gene Therapy Manufacturing
8.4. Market Attractiveness Analysis By Therapy Type
9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ billion) Analysis By Scale, 2018 to 2022
9.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Scale, 2023 to 2033
9.3.1. Pre-commercial/ R&D Scale Manufacturing
9.3.2. Gene Therapy Manufacturing
9.4. Market Attractiveness Analysis By Scale
10. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ billion) Analysis By Mode, 2018 to 2022
10.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Mode, 2023 to 2033
10.3.1. Contract Manufacturing
10.3.2. In-house Manufacturing
10.4. Market Attractiveness Analysis By Mode
11. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Workflow
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ billion) Analysis By Workflow, 2018 to 2022
11.3. Current and Future Market Size (US$ billion) Analysis and Forecast By Workflow, 2023 to 2033
11.3.1. Cell Processing
11.3.2. Cell Banking
11.3.3. Process Development
11.3.4. Fill & Finish Operations
11.3.5. Analytical And Quality Testing
11.3.6. Raw Material Testing
11.3.7. Vector Production
11.3.8. Other Workflows
11.4. Market Attractiveness Analysis By Workflow
12. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ billion) Analysis By Region, 2018 to 2022
12.3. Current Market Size (US$ billion) & Analysis and Forecast By Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. Asia Pacific
12.3.5. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
13.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
13.4.1. By Country
13.4.1.1. United States of America
13.4.1.2. Canada
13.4.1.3. Rest of North America
13.4.2. By Therapy Type
13.4.3. By Scale
13.4.4. By Workflow
13.4.5. By Mode
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Therapy Type
13.5.3. By Scale
13.5.4. By Workflow
13.5.5. By Mode
14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
14.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
14.4.1. By Country
14.4.1.1. Brazil
14.4.1.2. Mexico
14.4.1.3. Rest of Latin America
14.4.2. By Therapy Type
14.4.3. By Scale
14.4.4. By Workflow
14.4.5. By Mode
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Therapy Type
14.5.3. By Scale
14.5.4. By Workflow
14.5.5. By Mode
15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
15.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. France
15.4.1.3. United Kingdom
15.4.1.4. Italy
15.4.1.5. Benelux
15.4.1.6. Nordic Countries
15.4.1.7. Rest of Europe
15.4.2. By Therapy Type
15.4.3. By Scale
15.4.4. By Workflow
15.4.5. By Mode
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Therapy Type
15.5.3. By Scale
15.5.4. By Workflow
15.5.5. By Mode
16. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
16.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
16.4.1. By Country
16.4.1.1. China
16.4.1.2. Japan
16.4.1.3. South Korea
16.4.1.4. Rest of Asia Pacific
16.4.2. By Therapy Type
16.4.3. By Scale
16.4.4. By Workflow
16.4.5. By Mode
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Therapy Type
16.5.3. By Scale
16.5.4. By Workflow
16.5.5. By Mode
17. Middle East and Africa Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Value (US$ billion) Trend Analysis By Market Taxonomy, 2018 to 2022
17.4. Market Value (US$ billion) & Forecast By Market Taxonomy, 2023 to 2033
17.4.1. By Country
17.4.1.1. GCC Countries
17.4.1.2. South Africa
17.4.1.3. Turkey
17.4.1.4. Rest of Middle East and Africa
17.4.2. By Therapy Type
17.4.3. By Scale
17.4.4. By Workflow
17.4.5. By Mode
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Therapy Type
17.5.3. By Scale
17.5.4. By Workflow
17.5.5. By Mode
18. Key Countries Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. US Analysis
18.2.1. Value Proportion Analysis by Market Taxonomy
18.2.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.2.2.1. By Therapy Type
18.2.2.2. By Scale
18.2.2.3. By Workflow
18.2.2.4. By Mode
18.3. Canada Analysis
18.3.1. Value Proportion Analysis by Market Taxonomy
18.3.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.3.2.1. By Therapy Type
18.3.2.2. By Scale
18.3.2.3. By Workflow
18.3.2.4. By Mode
18.4. Mexico Analysis
18.4.1. Value Proportion Analysis by Market Taxonomy
18.4.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.4.2.1. By Therapy Type
18.4.2.2. By Scale
18.4.2.3. By Workflow
18.4.2.4. By Mode
18.5. Brazil Analysis
18.5.1. Value Proportion Analysis by Market Taxonomy
18.5.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.5.2.1. By Therapy Type
18.5.2.2. By Scale
18.5.2.3. By Workflow
18.5.2.4. By Mode
18.6. Germany Analysis
18.6.1. Value Proportion Analysis by Market Taxonomy
18.6.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.6.2.1. By Therapy Type
18.6.2.2. By Scale
18.6.2.3. By Workflow
18.6.2.4. By Mode
18.7. France Analysis
18.7.1. Value Proportion Analysis by Market Taxonomy
18.7.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.7.2.1. By Therapy Type
18.7.2.2. By Scale
18.7.2.3. By Workflow
18.7.2.4. By Mode
18.8. Italy Analysis
18.8.1. Value Proportion Analysis by Market Taxonomy
18.8.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.8.2.1. By Therapy Type
18.8.2.2. By Scale
18.8.2.3. By Workflow
18.8.2.4. By Mode
18.9. BENELUX Analysis
18.9.1. Value Proportion Analysis by Market Taxonomy
18.9.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.9.2.1. By Therapy Type
18.9.2.2. By Scale
18.9.2.3. By Workflow
18.9.2.4. By Mode
18.10. UK Analysis
18.10.1. Value Proportion Analysis by Market Taxonomy
18.10.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.10.2.1. By Therapy Type
18.10.2.2. By Scale
18.10.2.3. By Workflow
18.10.2.4. By Mode
18.11. Nordic Countries Analysis
18.11.1. Value Proportion Analysis by Market Taxonomy
18.11.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.11.2.1. By Therapy Type
18.11.2.2. By Scale
18.11.2.3. By Workflow
18.11.2.4. By Mode
18.12. China Analysis
18.12.1. Value Proportion Analysis by Market Taxonomy
18.12.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.12.2.1. By Therapy Type
18.12.2.2. By Scale
18.12.2.3. By Workflow
18.12.2.4. By Mode
18.13. Japan Analysis
18.13.1. Value Proportion Analysis by Market Taxonomy
18.13.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.13.2.1. By Therapy Type
18.13.2.2. By Scale
18.13.2.3. By Workflow
18.13.2.4. By Mode
18.14. South Korea Analysis
18.14.1. Value Proportion Analysis by Market Taxonomy
18.14.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.14.2.1. By Therapy Type
18.14.2.2. By Scale
18.14.2.3. By Workflow
18.14.2.4. By Mode
18.15. GCC Countries Analysis
18.15.1. Value Proportion Analysis by Market Taxonomy
18.15.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.15.2.1. By Therapy Type
18.15.2.2. By Scale
18.15.2.3. By Workflow
18.15.2.4. By Mode
18.16. South Africa Analysis
18.16.1. Value Proportion Analysis by Market Taxonomy
18.16.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.16.2.1. By Therapy Type
18.16.2.2. By Scale
18.16.2.3. By Workflow
18.16.2.4. By Mode
18.17. Turkey Analysis
18.17.1. Value Proportion Analysis by Market Taxonomy
18.17.2. Value Analysis and Forecast by Market Taxonomy, 2018-2033
18.17.2.1. By Therapy Type
18.17.2.2. By Scale
18.17.2.3. By Workflow
18.17.2.4. By Mode
18.17.3. Competition Landscape and Player Concentration in the Country
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Concentration
19.3. Market Share Analysis of Top Players
19.4. Market Presence Analysis
19.4.1. By Regional footprint of Players
19.4.2. Product footprint by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Thermo Fisher Scientific
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Sales Footprint
20.3.1.4. Strategy Overview
20.3.2. Merck KGaA
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Sales Footprint
20.3.2.4. Strategy Overview
20.3.3. Lonza
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Sales Footprint
20.3.3.4. Strategy Overview
20.3.4. Catalent Inc.
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Sales Footprint
20.3.4.4. Strategy Overview
20.3.5. Takara Bio Inc.
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Sales Footprint
20.3.5.4. Strategy Overview
20.3.6. F. Hoffmann-La Roche Ltd
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Sales Footprint
20.3.6.4. Strategy Overview
20.3.7. Wuxi Advanced Therapies
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Sales Footprint
20.3.7.4. Strategy Overview
20.3.8. Samsung Biologics
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Sales Footprint
20.3.8.4. Strategy Overview
20.3.9. Boehringer Ingelheim
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Sales Footprint
20.3.9.4. Strategy Overview
20.3.10. Novartis AG
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Sales Footprint
20.3.10.4. Strategy Overview
20.3.11. Hitachi Chemical Co., Ltd.
20.3.11.1. Overview
20.3.11.2. Product Portfolio
20.3.11.3. Sales Footprint
20.3.11.4. Strategy Overview
20.3.12. Cellular Therapeutics
20.3.12.1. Overview
20.3.12.2. Product Portfolio
20.3.12.3. Sales Footprint
20.3.12.4. Strategy Overview
20.3.12.5. Miltenyi Biotec Overview
20.3.12.6. Product Portfolio
20.3.12.7. Sales Footprint
20.3.12.8. Strategy Overview
20.3.13. Bluebird Bio Inc.
20.3.13.1. Overview
20.3.13.2. Product Portfolio
20.3.13.3. Sales Footprint
20.3.13.4. Strategy Overview
21. Assumptions and Acronyms Used22. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Billion), By Therapy Type, 2018 to 2022
Table 2: Global Market Value (US$ Billion), By Therapy Type, 2023 to 2033
Table 3: Global Market Value (US$ Billion), By Scale, 2018 to 2022
Table 4: Global Market Value (US$ Billion), By Scale, 2023 to 2033
Table 5: Global Market Value (US$ Billion), By Mode, 2018 to 2022
Table 6: Global Market Value (US$ Billion), By Mode, 2023 to 2033
Table 7: Global Market Value (US$ Billion), By Workflow, 2018 to 2022
Table 8: Global Market Value (US$ Billion), By Workflow, 2023 to 2033
Table 9: Global Market, By Region, 2018 to 2022
Table 10: Global Market, By Region, 2023 to 2033
Table 11: North America Market Value (US$ Billion), By Therapy Type, 2018 to 2022
Table 12: North America Market Value (US$ Billion), By Therapy Type, 2023 to 2033
Table 13: North America Market Value (US$ Billion), By Scale, 2018 to 2022
Table 14: North America Market Value (US$ Billion), By Scale, 2023 to 2033
Table 15: North America Market Value (US$ Billion), By Mode, 2018 to 2022
Table 16: North America Market Value (US$ Billion), By Mode, 2023 to 2033
Table 17: North America Market Value (US$ Billion), By Workflow, 2018 to 2022
Table 18: North America Market Value (US$ Billion), By Workflow, 2023 to 2033
Table 19: North America Market, By Country, 2018 to 2022
Table 20: North America Market, By Country, 2023 to 2033
Table 21: Latin America Market Value (US$ Billion), By Therapy Type, 2018 to 2022
Table 22: Latin America Market Value (US$ Billion), By Therapy Type, 2023 to 2033
Table 23: Latin America Market Value (US$ Billion), By Scale, 2018 to 2022
Table 24: Latin America Market Value (US$ Billion), By Scale, 2023 to 2033
Table 25: Latin America Market Value (US$ Billion), By Mode, 2018 to 2022
Table 26: Latin America Market Value (US$ Billion), By Mode, 2023 to 2033
Table 27: Latin America Market Value (US$ Billion), By Workflow, 2018 to 2022
Table 28: Latin America Market Value (US$ Billion), By Workflow, 2023 to 2033
Table 29: Latin America Market, By Country, 2018 to 2022
Table 30: Latin America Market, By Country, 2023 to 2033
Table 31: Europe Market Value (US$ Billion), By Therapy Type, 2018 to 2022
Table 32: Europe Market Value (US$ Billion), By Therapy Type, 2023 to 2033
Table 33: Europe Market Value (US$ Billion), By Scale, 2018 to 2022
Table 34: Europe Market Value (US$ Billion), By Scale, 2023 to 2033
Table 35: Europe Market Value (US$ Billion), By Mode, 2018 to 2022
Table 36: Europe Market Value (US$ Billion), By Mode, 2023 to 2033
Table 37: Europe Market Value (US$ Billion), By Workflow, 2018 to 2022
Table 38: Europe Market Value (US$ Billion), By Workflow, 2023 to 2033
Table 39: Europe Market, By Country, 2018 to 2022
Table 40: Europe Market, By Country, 2023 to 2033
Table 41: Asia Pacific Market Value (US$ Billion), By Therapy Type, 2018 to 2022
Table 42: Asia Pacific Market Value (US$ Billion), By Therapy Type, 2023 to 2033
Table 43: Asia Pacific Market Value (US$ Billion), By Scale, 2018 to 2022
Table 44: Asia Pacific Market Value (US$ Billion), By Scale, 2023 to 2033
Table 45: Asia Pacific Market Value (US$ Billion), By Mode, 2018 to 2022
Table 46: Asia Pacific Market Value (US$ Billion), By Mode, 2023 to 2033
Table 47: Asia Pacific Market Value (US$ Billion), By Workflow, 2018 to 2022
Table 48: Asia Pacific Market Value (US$ Billion), By Workflow, 2023 to 2033
Table 49: Asia Pacific Market, By Country, 2018 to 2022
Table 50: Asia Pacific Market, By Country, 2023 to 2033
Table 51: MEA Market Value (US$ Billion), By Therapy Type, 2018 to 2022
Table 52: MEA Market Value (US$ Billion), By Therapy Type, 2023 to 2033
Table 53: MEA Market Value (US$ Billion), By Scale, 2018 to 2022
Table 54: MEA Market Value (US$ Billion), By Scale, 2023 to 2033
Table 55: MEA Market Value (US$ Billion), By Mode, 2018 to 2022
Table 56: MEA Market Value (US$ Billion), By Mode, 2023 to 2033
Table 57: MEA Market Value (US$ Billion), By Workflow, 2018 to 2022
Table 58: MEA Market Value (US$ Billion), By Workflow, 2023 to 2033
Table 59: MEA Market, By Country, 2018 to 2022
Table 60: MEA Market, By Country, 2023 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Billion) and Year-on-Year Growth, 2018-2033
Figure 2: Global Market Absolute $ Historical Gain (2018 to 2022) and Opportunity (2023 to 2033), US$ Billion
Figure 3: Global Market Share, By Therapy Type, 2023 & 2033
Figure 4: Global Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Figure 5: Global Market Attractiveness Index, By Therapy Type – 2023 to 2033
Figure 6: Global Market Share, By Scale, 2023 & 2033
Figure 7: Global Market Y-o-Y Growth Projections, By Scale – 2023 to 2033
Figure 8: Global Market Attractiveness Index, By Scale – 2023 to 2033
Figure 9: Global Market Share, By Workflow, 2023 & 2033
Figure 10: Global Market Y-o-Y Growth Projections, By Workflow – 2023 to 2033
Figure 11: Global Market Attractiveness Index, By Workflow – 2023 to 2033
Figure 12: Global Market Share, By Mode, 2023 & 2033
Figure 13: Global Market Y-o-Y Growth Projections, By Mode – 2023 to 2033
Figure 14: Global Market Attractiveness Index, By Mode – 2023 to 2033
Figure 15: Global Market Share, By Region, 2023 & 2033
Figure 16: Global Market Y-o-Y Growth Projections, By Region – 2023 to 2033
Figure 17: Global Market Attractiveness Index, By Region – 2023 to 2033
Figure 18: North America Market Value (US$ Billion) and Year-on-Year Growth, 2018-2033
Figure 19: North America Market Absolute $ Opportunity Historical (2018 - 2022) and Forecast Period (2023 to 2033), US$ Billion
Figure 20: North America Market Share, By Therapy Type, 2023 & 2033
Figure 21: North America Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Figure 22: North America Market Attractiveness Index, By Therapy Type – 2023 to 2033
Figure 23: North America Market Share, By Scale, 2023 & 2033
Figure 24: North America Market Y-o-Y Growth Projections, By Scale – 2023 to 2033
Figure 25: North America Market Attractiveness Index, By Scale – 2023 to 2033
Figure 26: North America Market Share, By Workflow, 2023 & 2033
Figure 27: North America Market Y-o-Y Growth Projections, By Workflow – 2023 to 2033
Figure 28: North America Market Attractiveness Index, By Workflow – 2023 to 2033
Figure 29: North America Market Share, By Mode, 2023 & 2033
Figure 30: North America Market Y-o-Y Growth Projections, By Mode – 2023 to 2033
Figure 31: North America Market Attractiveness Index, By Mode – 2023 to 2033
Figure 32: North America Market Share, By Country, 2023 & 2033
Figure 33: North America Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 34: North America Market Attractiveness Index, By Country – 2023 to 2033
Figure 35: Latin America Market Value (US$ Billion) and Year-on-Year Growth, 2018-2033
Figure 36: Latin America Market Absolute $ Opportunity Historical (2018 - 2022) and Forecast Period (2023 to 2033), US$ Billion
Figure 37: Latin America Market Share, By Therapy Type, 2023 & 2033
Figure 38: Latin America Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Figure 39: Latin America Market Attractiveness Index, By Therapy Type – 2023 to 2033
Figure 40: Latin America Market Share, By Scale, 2023 & 2033
Figure 41: Latin America Market Y-o-Y Growth Projections, By Scale – 2023 to 2033
Figure 42: Latin America Market Attractiveness Index, By Scale – 2023 to 2033
Figure 43: Latin America Market Share, By Workflow, 2023 & 2033
Figure 44: Latin America Market Y-o-Y Growth Projections, By Workflow – 2023 to 2033
Figure 45: Latin America Market Attractiveness Index, By Workflow – 2023 to 2033
Figure 46: Latin America Market Share, By Mode, 2023 & 2033
Figure 47: Latin America Market Y-o-Y Growth Projections, By Mode – 2023 to 2033
Figure 48: Latin America Market Attractiveness Index, By Mode – 2023 to 2033
Figure 49: Latin America Market Share, By Country, 2023 & 2033
Figure 50: Latin America Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 51: Latin America Market Attractiveness Index, By Country – 2023 to 2033
Figure 52: Europe Market Value (US$ Billion) and Year-on-Year Growth, 2018-2033
Figure 53: Europe Market Absolute $ Opportunity Historical (2018 - 2022) and Forecast Period (2023 to 2033), US$ Billion
Figure 54: Europe Market Share, By Therapy Type, 2023 & 2033
Figure 55: Europe Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Figure 56: Europe Market Attractiveness Index, By Therapy Type – 2023 to 2033
Figure 57: Europe Market Share, By Scale, 2023 & 2033
Figure 58: Europe Market Y-o-Y Growth Projections, By Scale – 2023 to 2033
Figure 59: Europe Market Attractiveness Index, By Scale – 2023 to 2033
Figure 60: Europe Market Share, By Workflow, 2023 & 2033
Figure 61: Europe Market Y-o-Y Growth Projections, By Workflow – 2023 to 2033
Figure 62: Europe Market Attractiveness Index, By Workflow – 2023 to 2033
Figure 63: Europe Market Share, By Mode, 2023 & 2033
Figure 64: Europe Market Y-o-Y Growth Projections, By Mode – 2023 to 2033
Figure 65: Europe Market Attractiveness Index, By Mode – 2023 to 2033
Figure 66: Europe Market Share, By Country, 2023 & 2033
Figure 67: Europe Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 68: Europe Market Attractiveness Index, By Country – 2023 to 2033
Figure 69: MEA Market Value (US$ Billion) and Year-on-Year Growth, 2018-2033
Figure 70: MEA Market Absolute $ Opportunity Historical (2018 - 2022) and Forecast Period (2023 to 2033), US$ Billion
Figure 71: MEA Market Share, By Therapy Type, 2023 & 2033
Figure 72: MEA Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Figure 73: MEA Market Attractiveness Index, By Therapy Type – 2023 to 2033
Figure 74: MEA Market Share, By Scale, 2023 & 2033
Figure 75: MEA Market Y-o-Y Growth Projections, By Scale – 2023 to 2033
Figure 76: MEA Market Attractiveness Index, By Scale – 2023 to 2033
Figure 77: MEA Market Share, By Workflow, 2023 & 2033
Figure 78: MEA Market Y-o-Y Growth Projections, By Workflow – 2023 to 2033
Figure 79: MEA Market Attractiveness Index, By Workflow – 2023 to 2033
Figure 80: MEA Market Share, By Mode, 2023 & 2033
Figure 81: MEA Market Y-o-Y Growth Projections, By Mode – 2023 to 2033
Figure 82: MEA Market Attractiveness Index, By Mode – 2023 to 2033
Figure 83: MEA Market Share, By Country, 2023 & 2033
Figure 84: MEA Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 85: MEA Market Attractiveness Index, By Country – 2023 to 2033
Figure 86: Asia Pacific Market Value (US$ Billion) and Year-on-Year Growth, 2018-2033
Figure 87: Asia Pacific Market Absolute $ Opportunity Historical (2018 - 2022) and Forecast Period (2023 to 2033), US$ Billion
Figure 88: Asia Pacific Market Share, By Therapy Type, 2023 & 2033
Figure 89: Asia Pacific Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Figure 90: Asia Pacific Market Attractiveness Index, By Therapy Type – 2023 to 2033
Figure 91: Asia Pacific Market Share, By Scale, 2023 & 2033
Figure 92: Asia Pacific Market Y-o-Y Growth Projections, By Scale – 2023 to 2033
Figure 93: Asia Pacific Market Attractiveness Index, By Scale – 2023 to 2033
Figure 94: Asia Pacific Market Share, By Workflow, 2023 & 2033
Figure 95: Asia Pacific Market Y-o-Y Growth Projections, By Workflow – 2023 to 2033
Figure 96: Asia Pacific Market Attractiveness Index, By Workflow – 2023 to 2033
Figure 97: Asia Pacific Market Share, By Mode, 2023 & 2033
Figure 98: Asia Pacific Market Y-o-Y Growth Projections, By Mode – 2023 to 2033
Figure 99: Asia Pacific Market Attractiveness Index, By Mode – 2023 to 2033
Figure 100: Asia Pacific Market Share, By Country, 2023 & 2033
Figure 101: Asia Pacific Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Figure 102: Asia Pacific Market Attractiveness Index, By Country – 2023 to 2033
